GONDOLA AMPS SIGNED

Project "GONDOLA AMPS" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

+-

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Neurological conditions such as Parkinson’s and cerebral stroke cause motor disabilities, resulting in walking and balance impairment. These disorders severely affect patient’s independence and quality of life. State-of-the-art treatments and medications have little or no effect. Gondola AMPS is a game-changing proprietary medical device by Gondola Medical Technologies that delivers Automated Mechanical Peripheral Stimulation (AMPS). After treatment, most patients experience a drastic improvement of their motor symptoms. This non-invasive treatment takes less than two minutes and two applications a week are sufficient for a long-lasting effect. Gondola AMPS has already been adopted by 450 patients in several countries; boosted self-confidence and quality of life are consistently reported. The treatment can be delivered at home via a personalised device or at medical settings with a multi-patient device.

In the EU only, more than 7 million Parkinson patients and stroke survivors are affected by long-term disabilities and this will continue to grow at a rapid pace. Mobility losses and related care, equipment and infrastructure, bear huge costs estimated to represent an annual €50 billion. Gondola AMPS contributes to addressing this major economic and societal challenge. The invention is patent-protected in several countries. Ten clinical trials and as many peer-reviewed scientific publications conclude to the effectiveness of Gondola AMPS at strongly improving motor symptoms. Gondola AMPS brings a non-invasive and cost-effective answer to a widespread unmet medical need. Break-even is planned in less than three years while making Gondola Medical Technologies a global leader. To support this strong growth more than 150 highly qualified jobs will be created across Europe and eventually in USA, Canada and Japan.